Specify a stock or a cryptocurrency in the search bar to get a summary
ESSA Pharma Inc
EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Address: 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5
Analytics
WallStreet Target Price
19.8 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures EPIX
Dividend Analytics EPIX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History EPIX
Stock Valuation EPIX
Financials EPIX
Results | 2019 | Dynamics |